ROTH Capital Partners Acts as Sole Book-Running Manager for IRadimed Corporation (IRMD) in a $29.1 Million Secondary Offering

   

For more information please contact:

Investment Banking
Byron Roth
Chairman & CEO
(949) 720-5721
broth@roth.com

John Chambers
Vice-Chairman and
Head of Healthcare Investment Banking
(646) 358-1901
jchambers@roth.com

Adam Stormoen
Director
(612) 720-8136
astormoen@roth.com

Equity Capital Markets
Aaron Gurewitz
Head of Equity Capital Markets
(949) 720-5703
agurewitz@roth.com

Nazan Akdeniz
Senior Vice President
(949) 720-5740
nakdeniz@roth.com

Lou Ellis
Senior Vice President
(949) 720-5739
lellis@roth.com

Transaction Information
IRadimed Corporation (NASDAQ:IRMD) announced that Roger Susi, its President and Chief Executive Officer, completed the closing of an underwritten public offering of 1,200,000 shares of his common stock. The shares were sold at a public offering price of $24.25 per share, resulting in gross proceeds to Mr. Susi of approximately $29.1 million.

ROTH Capital Partners acted as the sole book-running manager for the offering.

About IRadimed Corporation
IRadimed Corporation is the only known provider of non-magnetic IV infusion pump systems that are designed to be safe for use during MRI procedures. Electromechanical medical devices and pumps contain magnetic and electronic parts which generate radio frequency (RF) noise, create interference and are dangerous to operate in the presence of the powerful magnet which drives an MRI. The company’s mRidium (3860+) IV pump system has been designed with non-ferrous parts, ceramic ultrasonic motors, non-magnetic mobile stand and other special features in order to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. The Company’s pump solution provides a seamless approach to providing IV fluids before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants must generally be sedated in order to remain immobile during an MRI scan. For more information please visit www.iradimed.com. mRidium is a trademark of IRadimed Corporation.

About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. and Hong Kong. For more information on ROTH, please visit www.roth.com.

  
 

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2016.